per una Endocrinologia 2.0

Aggiornamento Clinico Scientifico

A cura della Commissione Clinico Scientifica


  • Dott. Alessandro Peri

Delegato CD

  • Dott. Aldo Calogero


  • Dott. Daniele Gianfrilli (RM), andro e stili vita
  • Dott. Giuseppe Bellastella (NA2) andro e obesità
  • Dott. Massimo Procopio (TO)
  • Dott. Andrea Lania (MI)
  • Dott. Marco Baroni (RM) diabete
  • Dott.ssa Laura Trementino (PD)
  • Dott.ssa Flavia Prodam (NO)
  • Dott. Francesco Romanelli (RM)
  • Dott.ssa Annamaria De Bellis (NA2) 
  • Dott.ssa Tania Pilli (SI)


  • 18 gen 2016

    Aggiornamento Clinico Scientifico

    Outcomes in Relapsed Graves' Disease Patients Following Radioiodine or Prolonged Low Dose of Methimazole Treatment
    a cura di Tania Pilli
    Villagelin D, Romaldini JH, Santos RB, Milkos AB, Ward LS. 
    Background: Low doses of antithyroid drugs (ATD) for extended periods may be an alternative for Graves' disease (GD) patients who relapse after a course of ATD


  • 15 gen 2016

    Aggiornamento Clinico Scientifico

    Increased Hair Cortisol Concentrations and BMI in Patients With Pituitary-Adrenal Disease on Hydrocortisone Replacement
    a cura di Andrea Lania
    Sabine M. Staufenbiel, Cornelie D. Andela, Laura Manenschijn, Alberto M. Pereira, Elisabeth F. C. van Rossum, and Nienke R. Biermasz
    J Clin Endocrinol Metab. 2015 Jun;100(6):2456-62 

    Intrinsic imperfections and lack of reliable biomarkers preclude optimal individual dosing of hydrocortisone replacement in adrenal insufficiency (AI). However, the clinical relevance of optimal dosing


  • 12 gen 2016

    Aggiornamento Clinico Scientifico

    Sex Differences in the Cardiovascular Consequences of Diabetes Mellitus. A Scientific Statement From the American Heart Association
    a cura di Daniele Gianfrilli
    Regensteiner J.G., Golden S., Huebschmann A. G., Barrett-Connor E., Chang A. Y., Chyun D., Fox C. S., Kim C., Mehta N., Reckelhoff J. F., Reusch J. E.B., Rexrode K. M., Summer A. E., Welty F. K., Wenger N. K. and Anton B.
    Circulation. 2015 Dec 22;132(25):2424-47

    The prevalence of diabetes mellitus (DM) is increasing at a rapid rate. In the United State in 2012, 29.1 million Americans, or 9.3% of the population, had DM. Currently, ~1 in 13 people living in the United States has DM, and 90% to 95% of these individuals have type 2 DM (T2DM). 


  • 09 gen 2016

    Aggiornamento Clinico Scientifico

    Prevalence of autoimmune disease in patients with prolactinomas and non-functioning pituitary adenomas.
    a cura di  Annamaria De Bellis
    Larouche V, Correa JA, Cassidy P, Beauregard C, Garfield N, Rivera J.
    Pituitary. 2015 Dec 23.

    Prolactin can affect autoimmune response and evidence suggests that hyperprolactinemia can primarily precipitate autoimmunity. We postulate that patients with prolactinomas are more prone to autoimmune disease (AID).

  • 06 gen 2016

    Aggiornamento Clinico Scientifico

    Effect of testosterone treatment on cardiac biomarkers in a randomized controlled trial of men with type 2 diabetes
    a cura di Giuseppe Bellastella
    Emily J. Gianatti, Rudolf Hoermann, Que Lam, Philippe Dupuis, Jeffrey D. Zajac, and Mathis Grossmann
    Clinical Endocrinology (2016) 84, 55–62
    To assess the effect of testosterone treatment on cardiac biomarkers in men with type 2 diabetes (T2D). Design Randomized double-blind, parallel, placebo-controlled trial. Patients Men aged 35– 70 years with T2D and a total testosterone level 


  • 03 gen 2016

    Aggiornamento Clinico Scientifico

    Metformin as firstline treatment for type 2 diabetes: are we sure? 
    a curadi Marco Giorgio Baroni
    Boussageon R, Gueyffier F, Cornu C.
    BMJ. 2016 Jan 8;352:h6748. 

    Metformin is recommended as the first glucose lowering treatment for people with type 2 diabetes.1 The recommendation is based on the supposedly conclusive results of the UK Prospective Diabetes Study (UKPDS 34) published in 1998.



Novembre 2015

Settembre 2015

Copyright © 2019 | SICS S.r.l. - Via Boncompagni 16 - 00187 Roma | Partita IVA: 07639150965 - Tel. +39 06 89272802